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INTRODUCTION
Autism spectrum disorder (ASD) is characterized by impairments in social interactions, communication and repetitive behaviours. A prevalence of 1% in general population makes ASD one of the most prevalent disorders in childhood (1). The clinical phenotype is heterogeneous, and includes a broad range of comorbidities such as epilepsy, language impairment, anxiety, sleep disorders or attention-deficit hyperactivity disorder (ADHD) (2).
However, one of the most remarkable clinical features in ASD is represented by intellectual disability (ID), which is present in a considerable proportion of patients (3), and associated with the most severe phenotypic outcomes across the spectrum (4). ASD patients with higher intelligence quotient (IQ>70) and average or high cognitive abilities are often considered in a more homogenous clinical group referred to as high functioning autism (HFA).
Recent family studies confirm that genetic factors play a considerable role in ASD.
Heritability (h 2 =0.8) is one of the highest amongst neuropsychiatric disorders, with environmental factors minimally involved in disease risk (5) . Despite the high heritability, the specific genetic risk factors remain largely unknown, and only a small proportion of the approximately 1,000 genes estimated to be involved in ASD have been identified (6, 7).
The biological processes involved in ASD are yet to be fully determined, although evidence suggests that ASD may have a neuroinflammatory base (8), result from mitochondrial energetic deficits (9, 10), or considered a synaptopathology (11).
Genetic studies conducted over the last two decades converge on a genetic model in which both multiple common variants of small effect size and a discrete number of rare variants with higher penetrance, shape ASD genetic liability. The first genome-wide association studies (GWAS) pointed at several common variants in ASD (12-14), which were not replicated in a recent well-powered study of European populations (15) . Although common risk variants are estimated to explain approximately 20-50% of the genetics in ASD (16, 17) , larger cohorts are needed to identify individual allelic contributions (15) . Also the last efforts combining several large international GWAS datasets in a meta-analysis failed to identify genome-wide significant hits (18) .
Larger sample sizes and increased sensitivity in whole-exome or whole-genome sequencing studies (WES or WGS) have exponentially increased the identification of novel risk genes, setting the time to resolve most of the missing heritability in psychiatric diseases.
Several sequencing studies have implicated both rare de novo variants (DNs) and rare inherited single nucleotide variation (SNVs) in ASD (19) (20) (21) . The first WES studies implicated DN point mutations in disease pathogenesis in singleton ASD families (22) (23) (24) (25) , estimating that this mutation class may explain between 5-20% of genetic liability (23, 26, 27) . DN variants are considered highly deleterious, and an excess of DN truncating gene variants was found in autistic probands (24). Interestingly, several independent studies found a correlation between the higher burden of DN truncating variants and lower IQ in ASD (22, 23, 25) . Our group was the first to assess the impact of inherited rare variants in multiplex ASD families (28) , which suggested that apart from DN, inherited truncating variants also play a significant role in disease pathogenesis with a higher burden in ASD patients (28) . The contribution of inherited truncating variants in ASD was replicated later in a large sample by comparing probands and their unaffected siblings (29).
However, it is still unclear whether inherited truncating mutation burden is etiologically relevant in all autistic patients or if it is prominent only in those severe ASD cases associated with intellectual disability. Therefore, in this study we aimed to: i) determine whether rare inherited truncating mutations are distinctly implicated in high functioning autism; ii) identify molecular pathways or biological categories in ASD by considering the entire pool of severe mutations, including DN and inherited truncating variants; and iii) identify potential novel candidate genes for ASD. 
RESULTS

Inherited truncating alleles in high functioning autism
A total of 247 truncating alleles were validated after whole exome sequencing (WES) in 20
HFA families (47% indel-frameshift, 37% nonsense, 16% canonical splice-site variants) and are listed in supplementary material, Table S1 . We assessed whether the number of truncating alleles transmitted to HFA probands was higher than those non-transmitted, and found no significant difference across all families (z=0.992, P=0.32) (Table 1) , nor when considering each individual family (P>0.05). Moreover, no difference was observed after restricting analysis to truncating alleles in brain-expressed genes (z=0.207, P=0.84) (Table 1) . A similar ratio of transmitted/non-transmitted alleles was observed in unaffected siblings ( Table 1) .
Identification of de novo variants in HFA
We examined the impact of de novo (DN) variants across the 20 HFA families and 16 variants were validated: 13 missense, 2 synonymous and 1 splicing variant (supplementary material, Table S2 ). Missense variants, predicted pathogenic by both SIFT and PolyPhen-2, were found in PCDH15, ADD3, GALNT6 and TEX14, and a potential functional DN variant was found in a canonical acceptor splice site in LRP1 gene in one proband (Supplementary material, Fig. S1 ).
Enrichment analysis of inherited truncating and DN variants
We performed an enrichment analysis for Gene ontology (GO) categories and KEGG pathways of the combined pool of highly damaging variants including both inherited truncating alleles and DN variants found in the 20 HFA probands. Although categories with a plausible role in ASD were found in the top hits (Brain morphogenesis, P=0.001;
neurotransmitter receptor complex, P=0.003; histidine metabolism, P=0.023), none were significant after multiple correction (supplementary material, Table S3 and S4).
Enrichment analysis against gene-sets previously implicated in psychiatric disorders (30, 31) found no evidence of enrichment (Table 2) . However, the LRP1 gene was present in all gene-sets under study, namely: the post-synaptic density (PSD) genes, DN variants in ASD, DN variants in schizophrenia and FMRP target genes (Table 2) , warranting further investigation of this candidate gene.
LRP1 de novo splice site variant leads to skipping of exon 29 with functional consequences
The LRP1 DN variant found in proband SJD_33.3 (chr12:57573110, A/G) is located in a highly conserved canonical splice site and it is absent from the gnomAD database (http://gnomad.broadinstitute.org/). The AG to GG change is predicted to be functional and highly deleterious according to three splicing-based analysis tools: MaxEntScan (score=4.12), SPANR (dPSI-wt: 0; dPSI-mut: -12.95), and finally HSF (wt score: 86; mut score: 57), predicting a disrupted acceptor site of exon 29 ( Figure 1A-B ). Examination of LRP1 mRNA from the patient's blood lymphocytes confirmed an in-frame skipping of exon 29 ( Figure 1C ). The expression levels of transcripts from the mutated and WT alleles were similar (details in the Supplement). The LRP1 DN variant was also present in the patient's buccal cells from a saliva sample, which indicates a germline mutational origin and the presence of the abnormal transcript in all tissues where LRP1 is expressed, including brain.
Moreover, this DN mutation was absent in two additional unaffected siblings from this family.
To assess the potential functional consequences of exon 29 skipping (p.1580-1655del) at protein level, we performed a modelling study of the LRP1 protein domains Figure   2A ). Each of the β-propeller domains is the result of six YWTD repeats that are organized in six four-stranded β-sheets (blades) arranged radially about a central symmetry axis. We generated a structural model of the third and fourth LRP1 β-propeller domains, based on the homology of LRP6, which showed that exon 29 encodes the first two blades of the fourth βpropeller domain ( Figure 2B ). When we modelled the mutated form of LRP1, lacking the exon 29, the sequence alignment matched the β-propeller domains 3 and 5, whereas the βpropeller domain 4 segment was unaligned and cannot be folded into a globular structure.
However, the poor quality of the model does not exclude the possibility that the mutated βpropeller domain 4 may fold into an ordered structure.
To investigate whether LRP1 is involved in specific ASD networks of protein-protein interactions, we used ingenuity pathway analysis (IPA) with 75 genes that have previously been implicated in ASD. Interestingly, genes strongly associated to ASD such as SHANK3, FMR1, SYNGAP1 and GRIN2B were found in the same network with LRP1, being downstream of LRP1 in the signalling pathway (Supplementary material, Fig. S2 ).
Given findings suggesting the direct involvement of LRP1 in inflammatory response (32-34), we assessed whether the mutated form of LRP1 may compromise the inflammatory response by measuring IL-6, TNFα and IL-10 markers. Lower mRNA levels were found for all three cytokines in the patient's lymphoblastoid cell line compared to a control ( Figure 3 ).
Comparable results were obtained at the protein level for IL-10 and TNFα (Supplementary material, Fig. S3 ), whereas IL-6 was not detected from the assay. When we treated the lymphoblastoid cell line with lipopolysaccharide (LPS) to trigger an inflammatory response, a physiological pro-inflammatory response of IL-6 was observed in the control, but not in the patient cell line (Figure 3 ). Fig. S5 ). BrainCloud and SMRI Neuropathology Consortium datasets were used to assess potential effects of schizophrenia risk alleles on expression of LRP1, but rs12814239 and rs12826178 were not directly genotyped in these datasets, nor
other SNPs which would serve as reasonable surrogates (r 2 >0.7).
The identification of a functional DN variant in the LRP1 gene in an ASD family and the reported associations across the LRP1 locus in schizophrenia, prompted us to explore the impact of common, rare and DN variants of this gene in several large psychiatric datasets.
The NPdenovo and denovo-db databases report de novo variants in LRP1 in psychiatric disease projects (supplementary material, Table S5 ). These DN variants include three highly pathogenic variants, all absent from gnomAD database: a stop mutation from a schizophrenia patient (p.Y2200*), a frame-shift from an ID patient (p.Q3380Sfs*72), and an exon 29 variant in an ASD patient, which is likely to disrupt an exonic splicing enhancer (ESE) site with an effect potentially similar to that reported in patient SJD_33.3. NPdenovo data showed association of DN in LRP1 with ASD (P=0.039), ID (P=0.008) and SCZ (P=0.008).
We also explored the possible contribution of common variants in LRP1 by performing a gene-based association study using summary statistics from PGC GWAS data in European populations, which suggests common variants in LRP1 increase risk of schizophrenia (Gene-based P=6.6E-07), and a trend for ADHD and bipolar disorder, but not in the ASD sample (Table 3) . A meta-analysis combining data from six psychiatric disorders strongly implicates LRP1 common variants across these conditions (P=8.1E-05) ( Table 3) .
A burden analysis using a combined multivariate and collapsing method (CMC) was performed to assess the impact of predicted pathogenic rare or ultra-rare variants (URVs, MAF<0.0001) of LRP1 in schizophrenia (Swedish case-control) and in the Autism (BCM case-control) data sets. No differences were found in schizophrenia (P=0.63), but a significant burden was observed in autism probands (P=0.048). When data for each phenotype were combined (7,875 control individuals, 6,135 schizophrenic patients and 1,778 ASD probands) no difference in the URVs were observed between schizophrenic patients and controls (P=0.52), whereas a higher burden was observed in ASD patients (P=1.2E-05) (Table 4 and supplementary material, Table S6 ). 
DISCUSSION
Recent sequencing studies have strongly implicated de novo and inherited pathogenic rare variants in ASD (19-29). However, these variants seem to have a varying impact across the heterogeneous ASD phenotype. While the contribution of DN truncating variants has been extensively described in ASD probands with lower IQ, insufficient data are available in regards to inherited truncating variants. A previous study from our group found a higher burden for co-inherited truncating variants in ASD sib-pairs (28), and the burden of these disruptive alleles correlated negatively with non-verbal IQ (NVIQ) (28). Another study showed a significant impact for inherited gene disrupting variants in ASD probands with lower than average IQ (<100) compared with unaffected siblings (29). In the present study we have assessed the impact of rare inherited truncating variants by comparing those that were transmitted vs non-transmitted in singleton families with high function autism (HFA) to establish whether highly disruptive variants have a role in all cases of ASD regardless their comorbidity with intellectual disability. Our results showed no preferential burden transmission from parents to HFA probands, suggesting that truncating alleles may not have a major role across the entire disease spectrum, but may be restricted to those ASD patients with ID.
Correlation between severe disrupting mutations and severe phenotypes has also been reported for other psychiatric diseases: a higher rate of rare truncating variants was found in schizophrenia patients with intellectual disability (36), and in bipolar disorder the burden of inherited truncating alleles was negatively correlated with early age of onset (31). Rare CNV or ultra-rare disruptive alleles were also found associated with lower educational attainment in the general population (37, 38), suggesting that this class of genetic variants may negatively modulate cognitive functions. In summary, all these findings suggest that there is a correlation between the burden of severe mutations and the severity of the disease phenotype. In our study we also performed enrichment analyses in the list of genes bearing transmitted truncating alleles and DN in HFA probands. No enrichments were observed when we considered this pool of genes, but interestingly, LRP1 (low-density lipoprotein receptorrelated protein-1) recurrently appeared in all psychiatric-related gene-sets. The DN variant found in a HFA patient in LRP1 is not present in the gnomAD database (138,632 sequenced individuals) and is predicted to disrupt an acceptor splice site. The consequence of this mutation at RNA level is an in-frame skipping of exon 29, which removes two out of six radial blades of the β-propeller 4 of LRP1. It is likely that the β-propeller 4 is not folded in a functional canonical domain, potentially compromising interactions at this and adjacent 3 and 5 β-propellers.
We then investigated the possible involvement of this gene in several psychiatric disorders by exploring a number of genetic datasets. We identified an association of DN variants in LRP1 with autism and schizophrenia, an association of common variants at gene level in schizophrenia plus an association in a meta-analysis of six psychiatric disorders, and a significant impact for ultra-rare pathogenic variants in ASD. These results implicate common and rare variants in LRP1 gene across several psychiatric phenotypes. Interestingly, although LRP1 is ubiquitously expressed, higher expression is found in postnatal cerebral stages, when abnormalities in brain are observed in autistic patients (39) . Studies in mice also suggested a peak of LRP1 expression during early postnatal brain development in several populations of cells including radial glia, immature and mature neurons, microglia and astrocytes (40).
LRP1 has a dual role, being involved in endocytosis and signal transduction, and it binds approximately 40 extracellular ligands mediating a multitude of physiological processes (41). The DN mutation found in a HFA proband in this study affects the structure of a β-propeller domain, which may impair ligand dissociation and the formation of early Considering the high number of ligands and pathways mediated by LRP1, it is difficult to pinpoint a specific compromised pathophysiological process. However, several plausible hypotheses can be formulated in relation to its impact on postsynaptic complexes, its role in inflammatory response, insulin signalling, and lipid homeostasis. Firstly, LRP1 encodes a PSD protein, and plays a role in synaptic integrity and function at the postsynapses by regulating GRIA1 (45), implicated in learning disabilities and autism through de novo gain-of-function mutations causing constitutive calcium-channel opening (21). We found LRP1 in the same network of well-established ASD genes such as SHANK3, GRIN2B
and SYNGAP1. The role of PSD genes in psychiatry has solid evidence (24, 31, 46 patients in an extended family (31). Finally, LRP1 may exert its effects via impairment of lipid homeostasis. Knockout mice showed that neuronal LRP1 is critical for cholesterol and lipid metabolism, and its defect leads to dendritic spine degeneration, synapse loss and neuroinflammation (50). However, it is likely that etiologic genetic variants of LRP1 exert their role in psychiatric diseases by concurrently impairing more than one pathway at the same time.
It is noteworthy that other lipoprotein receptors from the same family such as LRP2, LRP1B and LRP8 have previously been implicated in autism and psychosis (51-53),
suggesting an emerging role for this gene family in psychiatric disorders.
In conclusion, considering our previous and current results, and additional sequencing findings we provide evidence of a relationship between severe mutations and severe ASD phenotype: the accumulation of inherited truncating mutations lead to a more severe phenotype in autism, whereas their impact in high cognitive patients would be limited.
Furthermore, we show through a comprehensive analysis of DN, common and rare variants that LRP1 is a candidate gene with pleiotropic effects across multiple psychiatric phenotypes. 
MATERIALS AND METHODS
Selection of ASD subjects and phenotypic assessment
From our collection of ASD families (54, 55), we selected 20 singleton Spanish families without any other psychiatric history amongst relatives. All probands had high functioning autism (HFA), which defined as having full scale IQ greater than 70 (IQ average=100, SD±14.7, range 80-135). Clinical description is provided in the supplementary material, Table S7 .
Exome sequencing and WES-based genetic relatedness analysis
The sequenced sample included 60 individuals (40 parents and 20 ASD probands). Exome enrichment was performed on 3 μg of genomic DNA extracted from blood, and the exome libraries were applied to an Illumina flowcell for paired-end sequencing on a HiSeq2000 instrument (Illumina) using 76-base reads. Detailed bioinformatic analysis is provided in the Supplement. On average, individuals had 82.1% of the target covered by >10 reads (Supplementary material, Table S8 ). Familial relationships were confirmed by genome-wide Identity By Descendent (IBD) analysis in PLINK (56), using WES-derived genotypes (details in the Supplement).
Variant selection: Rare truncating alleles and de novo variants
Rare variants were defined as those having a minor allele frequency (MAF) <1% in dbSNP135. The truncating alleles selected included nonsense, indels leading to frame-shift, variants in canonical splice sites and start-lost changes. For each family truncating alleles both transmitted to the ASD proband and non-transmitted (i.e. only in parents) were considered. We also examined de novo (DN) variants. Rare truncating alleles and DN variants were all validated (N=263) by Sanger sequencing. During variant validation, we included also 9 unaffected siblings from 8 families to assess the transmission of inherited truncating alleles from parents.
Enrichment analyses
Enrichment of genes carrying inherited truncating alleles and DN variants were tested against all Gene Ontology (GO) categories and KEGG pathways. Enrichment analysis were also performed using the same pool of genes against several gene sets potentially related to ASD, namely: genes encoding postsynaptic density proteins (PSD) (57), fragile-X mental retardation protein (FMRP) targets (58), de novo variants previously found in autism and schizophrenia (30). Both analyses were performed by: i) matching genes carrying potentially truncating or DN variants to genes randomly drawn from the genome, after approximate matching on exome enriched coding-sequence length and genic constraint missense Z-score (http://exac.broadinstitute.org) (59); and ii) calculating an empirical p-value for observed data for each functional category, using a null distribution of overlap counts from 1,000 randomly drawn gene sets, as described previously (31).
Effect of LRP1 de novo mutation on splicing
Functional predictions for the de novo splice site variant in LRP1 (chr12:57573110A/G) were performed using three tools: MaxEntScan (60), SPANR (61) and Human Splicing Finder (HSF) (62). To assess functional consequences at RNA level we used cDNA from peripheral blood mononuclear cells (PBMC) of the SJD_33.3 ASD patient (details in the Supplement).
PCR products from primers designed in exon 28 and 30 were separated by 10% polyacrylamide gel electrophoresis, and the intensity of the 2 resulting bands measured by a semi-quantitative method (details in the Supplement).
Protein modelling of LRP1: Consequence of the in-frame skipping of exon 29
The LRP1 wild-type protein was modelled using the Swiss-model platform (63, 64) that was enquired to search homologous templates using the LRP1 full length sequence (details in the Supplement). The selected model was generated from template 3s94.1.A, corresponding to the structure of the beta-propeller domains 1 and 2 of the human LRP6 (PDB ID 3s94) (65).
The LRP1 protein model that includes exon 29 was examined using both SWISS-MODEL and the Robetta server (66, 67).
LRP1 gene network analysis
We investigated whether LRP1 was included in a network of genes previously implicated in ASD using Ingenuity Pathway Analysis (IPA) software (www.ingenuity.com). We computed the most likely network of interactions given a pool of 75 genes with a high probability of involvement in ASD selected from the SFARI database (categories S and 1) (https://gene.sfari.org/database/gene-scoring/).
Effect of the LRP1 mutated form on inflammatory biomarkers
RNA was extracted from patient SJD_33.3 and a control lymphoblastoid cell line and cDNA was prepared (details in Supplement). We performed quantitative Real-Time PCR (qPCR) and ELISA for the following cytokines: IL-6 and TNFα (pro-inflammatory response), and IL-10 (anti-inflammatory response). Details of these experiments and primers are provided in the Supplementary material, Table S9 . 
LRP1: de novo, common and rare variant analyses in psychiatric diseases
Two databases for de novo variants were used to identify previous DN in LRP1 (68, 69) .
NPdenovo was used to assess the overall DN association between LRP1 and several neuropsychiatric diseases: ASD (6,118 families), SCZ: (1,164 families), epilepsy (647 families) and ID (1,101 families) (68).
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